Intestinal Cell News 4.29 August 3, 2018 | |
| |
TOP STORYScientists demonstrated that epithelial IMP1 loss increased expression of WNT target genes and enhanced LIN28B-mediated intestinal tumorigenesis, which was reversed when they overexpressed IMP1 independently in vivo. [Genes Dev] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Manic Fringe Deficiency Imposes Jagged1 Addiction to Intestinal Tumor Cells Investigators found that intestinal-specific Jag1 deletion or antibody targeting Jag1 prevented tumor initiation in mice. Addiction to Jag1 was concomitant with the absence of Manic Fringe in adenoma cells, and its ectopic expression reverted Jag1 dependence. [Nat Commun] Full Article | Press Release The attenuation of homologous recombination activity decreased the numbers of double minutes (DMs) and DM-form amplified gene copies and increased the exclusion of micronuclei and nuclear buds that contained DM-form amplification; these changes were accompanied by cell cycle acceleration and increased MTX sensitivity. [Int J Cancer] Abstract MASTL Induces Colon Cancer Progression and Chemoresistance by Promoting Wnt/β-Catenin Signaling MASTL expression facilitated colon cancer progression by promoting β-catenin/Wnt signaling, the key signaling pathway implicated in colon carcinogenesis, and up-regulating anti-apoptotic proteins, Bcl-xL and Survivin. 5-fluorouracil treatment revealed a sharp increase in MASTL expression upon chemotherapy, along with increases in Bcl-xL and Survivin expression. [Mol Cancer] Full Article ER Stress-Related ATF6 Upregulates CIP2A and Contributes to Poor Prognosis of Colon Cancer The authors found that ATF6 directly bound to the cancerous inhibitor of protein phosphatase 2A (CIP2A) promoter and induced CIP2A gene expression, which contributed to colon cancer cell survival. Knockdown of CIP2A reduced the viability of cells under ER stress. [Mol Oncol] Abstract | Full Article Investigators found miR-181b was a direct regulator of protein inhibitor of activated STAT3 (PIAS3). miR-181b promoted the Warburg effect and the growth of colon cancer xenografts; however, these effects could be reversed by PIAS3. [J Cell Mol Med] Abstract | Full Article Researchers showed that water stress protein (WSP1) inhibited DLD-1 cell migration, but had an insignificant effect on normal human colon epithelial cells. They indicated that WSP1 activated autophagy through the down regulation of the PI3K/AKT/mTOR pathway. [Int J Biol Macromol] Abstract Human induced pluripotent cells were differentiated into intestinal stem cells using activin A and fibroblast growth factor 2. The intestinal stem cells were matured into intestinal epithelial cells by treatment with 8-bromo-cyclic adenosine monophosphate and 3-isobutyl-1-methylxanthine, which activate cAMP signaling. [Drug Metab Dispos] Abstract | Full Article Combined treatment with resveratrol and piceatannol decreased tumor cell survival as indicated by the upregulation of the DNA damaging marker, γH2AX, the cleavage of caspase 3, the downregulation of the survival markers, p38-MAPK/c-Myc, and G1-to-S cell cycle arrest. [Int J Oncol] Abstract Scientists found that 17 miRNAs including miR-146a were upregulated and 16 miRNAs were downregulated in FPCKpP1-4 adenocarcinoma cells. They revealed that miR-146a in the adenocarcinoma cells brought about acquisition of sphere formation, cancer stemness, and inhibition of proteasomal degradation of the fascin protein. [Inflamm Res] Abstract Subscribe to one of our other 19 science newsletters such as Pulmonary Cell News & ESC & iPSC News. | |
| |
REVIEWSNeuroimmunophysiology of the Gut: Advances and Emerging Concepts Focusing on the Epithelium The latest discoveries shed light on the sophisticated intracellular, intercellular and interkingdom signaling mechanisms of host defense that involve epithelial and enteroendocrine cells, the enteric nervous system and the immune system. Therapeutic strategies are being developed that target these signaling systems to improve the resilience of the gut and treat the symptoms of gastrointestinal disease. [Nat Rev Gastroenterol Hepatol] Abstract Visit our reviews page to see a complete list of reviews in the intestinal cell research field. | |
| |
INDUSTRY NEWSLilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute Under the agreement, Dana-Farber researchers were, and will continue to be, granted permission to conduct independent pre-clinical and clinical studies on select Lilly compounds. All compounds evaluated through this collaboration will continue to be fully owned by Lilly. Financial terms of the agreement were not disclosed. [Eli Lilly and Company] Press Release Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the Marketing Authorization Application of Hulio™ the companies’ biosimilar to Humira®, for all indications. [Mylan N.V] Press Release RedHill Biopharma Ltd. reiterates that its MAP US first Phase III study with RHB-104 successfully met its primary endpoint, as well as key secondary endpoints, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104. [RedHill] Press Release | |
| |
| |
POLICY NEWSGigantic Review of German Science Recommends More Data and Diversity Germany’s largest research organization is funding top-notch science, but it needs to employ more foreign and female researchers — and it is failing to leverage ‘big data’, such as electronic medical records. [Nature News] Editorial Brexit Preparedness: EMA to Further Temporarily Scale Back and Suspend Activities The European Medicines Agency (EMA) will launch the next phase of its business continuity plan on 1 October 2018 at the latest. This will allow the Agency to safeguard core activities related to the evaluation and supervision of medicines, while it has to intensify its preparations for the physical move to Amsterdam in March 2019 and cope with significant staff loss. [European Medicines Agency] Press Release March of Dimes Abruptly Scales Back Research Funding March of Dimes, the 80-year-old nonprofit organization that has funded pioneering studies on premature birth, infant mortality, and birth defects, is abruptly scaling back its investment in research amid financial struggles-catching scientists by surprise. [ScienceInsider] Editorial Series of Ethical Stumbles Tests NIH’s Reliance on Private Sector for Research Funding NIH officials told STAT the agency is completing a plan to ensure better ethical compliance and better delineate the actual process for private-sector collaboration. The officials said the plan will be presented to an advisory committee in December. [STAT News] Editorial
| |
EVENTSNEW 11th American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA) Joint Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Signal Transduction of Intestinal Cells (Mornell Chemical Senses Center) Postdoctoral Fellow – Colon Cancer (Vanderbilt University Medical Center) Senior Research Scientist – Cancer Research (Memorial Sloan Kettering Cancer Center) Postdoctoral Position – Paneth Cells (Erasmus MC Cancer Institute) Postdoctoral Scholar – Molecular and Cell Biology (University of California, Berkeley) Assistant Professor – Cancer Biology (Université de Genève) Postdoctoral Fellow – Colorectal Cancer (Dalhousie University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Intestinal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|